| Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. | |
| | |
MedLine Citation:
|
PMID: 18519851 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy. METHODS AND RESULTS: A post hoc analysis was performed that combined data from 2 prospective, randomized clinical trials in which 10,001 ("Treating to New Targets") and 8888 ("Incremental Decrease in End Points through Aggressive Lipid Lowering") patients with established coronary heart disease were assigned to usual-dose or high-dose statin treatment. In models with LDL cholesterol, non-HDL cholesterol and apolipoprotein B were positively associated with cardiovascular outcome, whereas a positive relationship with LDL cholesterol was lost. In a model that contained non-HDL cholesterol and apolipoprotein B, neither was significant owing to collinearity. Total/HDL cholesterol ratio and the apolipoprotein B/A-I ratio in particular were each more closely associated with outcome than any of the individual proatherogenic lipoprotein parameters. CONCLUSIONS: In patients receiving statin therapy, on-treatment levels of non-HDL cholesterol and apolipoprotein B were more closely associated with cardiovascular outcome than levels of LDL cholesterol. Inclusion of measurements of the antiatherogenic lipoprotein fraction further strengthened the relationships. These data support the use of non-HDL cholesterol or apolipoprotein B as novel treatment targets for statin therapy. Given the absence of interventions that have been proven to consistently reduce cardiovascular disease risk through raising plasma levels of HDL cholesterol or apolipoprotein A-I, it seems premature to consider the ratio variables as clinically useful. |
| | |
Authors:
|
John J P Kastelein; Wim A van der Steeg; Ingar Holme; Michael Gaffney; Nilo B Cater; Philip Barter; Prakash Deedwania; Anders G Olsson; S Matthijs Boekholdt; David A Demicco; Michael Szarek; John C LaRosa; Terje R Pedersen; Scott M Grundy; ; |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-06-02 |
Journal Detail:
|
Title: Circulation Volume: 117 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-06-10 Completed Date: 2008-07-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 3002-9 Citation Subset: AIM; IM |
Affiliation:
|
Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, the Netherlands. j.j.kastelein@amc.uva.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Apolipoprotein A-I / blood Apolipoproteins B / blood* Cholesterol, HDL / blood Cholesterol, LDL / blood Coronary Disease / blood*, epidemiology, prevention & control* Databases, Factual Dyslipidemias / blood, drug therapy Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Lipids / blood* Male Middle Aged Proportional Hazards Models Randomized Controlled Trials as Topic Risk Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Triglycerides |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to repe...
Next Document: Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology.